Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

[11C]Deschloroclozapine is an improved PET radioligand for quantifying a human muscarinic DREADD expressed in monkey brain

Xuefeng Yan, Sanjay Telu, Rachel Dick, Jeih-San Liow, Paolo Zanotti-Fregonara, Cheryl Morse, Lester Manly, Robert Gladding, Stal Shrestha, Walter Lerchner, Yuji Nagai, Takafumi Minamimoto, Sami Zoghbi, Robert Innis, Victor Pike, Barry Richmond and Mark Eldridge
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 120;
Xuefeng Yan
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sanjay Telu
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rachel Dick
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeih-San Liow
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paolo Zanotti-Fregonara
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cheryl Morse
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lester Manly
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Gladding
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stal Shrestha
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Walter Lerchner
2Laboratory of Neuropsychology, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yuji Nagai
3Department of Functional Brain Imaging, National institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takafumi Minamimoto
3Department of Functional Brain Imaging, National institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology Chiba Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sami Zoghbi
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Innis
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Victor Pike
1Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry Richmond
2Laboratory of Neuropsychology, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Eldridge
2Laboratory of Neuropsychology, National Institute of Mental Health, National Institutes of Health Bethesda MD United States
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

120

Introduction: A previous study found that [11C]deschloroclozapine ([11C]DCZ) is a superior radiotracer to [11C]clozapine ([11C]CLZ) for imaging DREADDS1. Building on this work, the present study used PET to quantitatively and separately measure the signal from transfected receptors, endogenous receptors/targets, and non-displaceable binding in other brain regions in order to assess the qualities that contribute to this superiority. Methods: A genetically modified muscarinic type 4 human receptor (hM4Di) was injected into the right amygdala of an 11-year-old male rhesus macaque. PET scans with [11C]DCZ and [11C]CLZ were conducted two to 24 months later. Uptake was quantified relative to the concentration of parent radioligand in arterial plasma at baseline (n=3 scans/radioligand) and after receptor blockade (n=3 scans/radioligand). For [11C]CLZ, the three blocking studies and i.v. doses were: a) clozapine-N-oxide (CNO) (10 mg/kg), b) CLZ (0.1 mg/kg), and c) clotrimazole (CTM; 1 mg/kg) plus CNO (10 mg/kg). For [11C]DCZ, the three blocking studies and i.v. doses were: a) CNO (10mg/kg), b) low-dose DCZ (0.1 mg/kg), and c) high-dose DCZ (1 mg/kg). To assess the radiotracers’ transfer between plasma and brain quantitatively, eight different VOI-based methods were performed: the one- and two-tissue compartment models, Ichise’s multilinear reference tissue models (MRTM, MRTM0, and MRTM2), simplified reference models (SRTM and SRTM2), and Logan’s reference tissue model (Logan-REF). The cerebellum was used as the reference region.

Results: Both radioligands had greater uptake in the transfected region and displaceable uptake in other brain regions. Displaceable uptake was not uniformly distributed and might represent off-target binding to endogenous receptor(s). After correction, the [11C]DCZ signal was 19% of that for [11C]CLZ, and the background uptake of [11C]DCZ was 10% of that for [11C]CLZ. Despite stronger binding of [11C]CLZ, the signal-to-background ratio for [11C]DCZ was almost two-fold greater than for [11C]CLZ. Both radioligands had comparable DREADD selectivity. All reference tissue models underestimated signal-to-background ratio in the transfected region by 40%-50% for both radioligands.Conclusion: Both [11C]DCZ and [11C]DCZ had high-affinity displaceable binding to DREADDs relative to endogenous receptor(s), However, the signal-to-background ratio of [11C]DCZ was greater than that of [11C]CLZ primarily because of lower nonspecific binding of [11C]DCZ. Reference tissue models underestimated the signal-to-background ratio compared to two tissue compartmental model. Nevertheless, the use of a pseudo-reference region should provide useful information on the localization and comparative quantitation of the transfected receptor. Our results confirm that [11C]DCZ is far superior to [11C]CLZ to image the hM4Di DREADD for behavioral and translational experiments.References: 1. Nagai Y, Miyakawa N, Takuwa H, et al. Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys. Nature Neuroscience volume 23, pages1157-1167(2020)

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
[11C]Deschloroclozapine is an improved PET radioligand for quantifying a human muscarinic DREADD expressed in monkey brain
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
[11C]Deschloroclozapine is an improved PET radioligand for quantifying a human muscarinic DREADD expressed in monkey brain
Xuefeng Yan, Sanjay Telu, Rachel Dick, Jeih-San Liow, Paolo Zanotti-Fregonara, Cheryl Morse, Lester Manly, Robert Gladding, Stal Shrestha, Walter Lerchner, Yuji Nagai, Takafumi Minamimoto, Sami Zoghbi, Robert Innis, Victor Pike, Barry Richmond, Mark Eldridge
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 120;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
[11C]Deschloroclozapine is an improved PET radioligand for quantifying a human muscarinic DREADD expressed in monkey brain
Xuefeng Yan, Sanjay Telu, Rachel Dick, Jeih-San Liow, Paolo Zanotti-Fregonara, Cheryl Morse, Lester Manly, Robert Gladding, Stal Shrestha, Walter Lerchner, Yuji Nagai, Takafumi Minamimoto, Sami Zoghbi, Robert Innis, Victor Pike, Barry Richmond, Mark Eldridge
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 120;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Optimization of 89Zr PET imaging using both phantom and clinical studies with [89Zr]-Df-IAB22M2C, an anti-CD8 minibody.
  • Progression and toxicity following liver Y90 radioembolization: impact of dose metrics, clinical factors, and biomarkers
  • Explainable prediction of all-cause mortality from myocardial PET flow and perfusion images using deep learning
Show more Oral - PhysicianPharm

Novel Radiotracers and Multi-Modal Imaging of the Brain

  • [C-11]UCB-J uptake and Ab accumulation across the cognitive spectrum
  • Associations between 11C-UCB-J source networks and fMRI resting-state networks
  • Human hippocampal [18F]nifene binding to nicotinic acetylcholinergic α4β2* receptors is reduced in postmortem Alzheimer’s disease brains
Show more Novel Radiotracers and Multi-Modal Imaging of the Brain

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire